KR101617812B1 - 비알콜성 지방간 질환을 위한 신규 조성물 - Google Patents

비알콜성 지방간 질환을 위한 신규 조성물 Download PDF

Info

Publication number
KR101617812B1
KR101617812B1 KR1020157024370A KR20157024370A KR101617812B1 KR 101617812 B1 KR101617812 B1 KR 101617812B1 KR 1020157024370 A KR1020157024370 A KR 1020157024370A KR 20157024370 A KR20157024370 A KR 20157024370A KR 101617812 B1 KR101617812 B1 KR 101617812B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
fatty liver
sodium
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157024370A
Other languages
English (en)
Korean (ko)
Other versions
KR20150118990A (ko
Inventor
판카지 파텔
자니 라젠드라쿠마르 하리프라사드
Original Assignee
카딜라 핼쓰캐어 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카딜라 핼쓰캐어 리미티드 filed Critical 카딜라 핼쓰캐어 리미티드
Publication of KR20150118990A publication Critical patent/KR20150118990A/ko
Application granted granted Critical
Publication of KR101617812B1 publication Critical patent/KR101617812B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020157024370A 2013-04-22 2013-06-25 비알콜성 지방간 질환을 위한 신규 조성물 Active KR101617812B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1468/MUM/2013 2013-04-22
IN1468MU2013 IN2013MU01468A (cg-RX-API-DMAC10.html) 2013-04-22 2013-06-25
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)

Publications (2)

Publication Number Publication Date
KR20150118990A KR20150118990A (ko) 2015-10-23
KR101617812B1 true KR101617812B1 (ko) 2016-05-03

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024370A Active KR101617812B1 (ko) 2013-04-22 2013-06-25 비알콜성 지방간 질환을 위한 신규 조성물

Country Status (21)

Country Link
US (3) US20160166539A1 (cg-RX-API-DMAC10.html)
EP (1) EP2988736A1 (cg-RX-API-DMAC10.html)
JP (1) JP6246895B2 (cg-RX-API-DMAC10.html)
KR (1) KR101617812B1 (cg-RX-API-DMAC10.html)
CN (1) CN105377246B (cg-RX-API-DMAC10.html)
AP (1) AP2015008674A0 (cg-RX-API-DMAC10.html)
AU (1) AU2013387996B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015020600A2 (cg-RX-API-DMAC10.html)
CA (1) CA2900435C (cg-RX-API-DMAC10.html)
EA (1) EA201592020A1 (cg-RX-API-DMAC10.html)
GE (1) GEP201706663B (cg-RX-API-DMAC10.html)
HK (1) HK1214968A1 (cg-RX-API-DMAC10.html)
IL (2) IL240183A (cg-RX-API-DMAC10.html)
IN (1) IN2013MU01468A (cg-RX-API-DMAC10.html)
MA (1) MA38385A1 (cg-RX-API-DMAC10.html)
MX (1) MX346943B (cg-RX-API-DMAC10.html)
MY (1) MY180160A (cg-RX-API-DMAC10.html)
PH (1) PH12015501795A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201506218UA (cg-RX-API-DMAC10.html)
UA (1) UA114360C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014174524A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (cg-RX-API-DMAC10.html) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (cg-RX-API-DMAC10.html) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN109069503A (zh) * 2016-04-22 2018-12-21 景凯生物科技股份有限公司 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用
EP3551180B1 (en) * 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US12201609B2 (en) * 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2022128870A1 (en) * 2020-12-18 2022-06-23 Société des Produits Nestlé S.A. Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol
US20220378786A1 (en) * 2021-05-21 2022-12-01 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009841A1 (en) 2001-07-26 2003-02-06 Cadila Healthcare Limited Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US6075140A (en) 1995-04-28 2000-06-13 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compound
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1124807A1 (en) 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ES2449194T3 (es) 2000-01-19 2014-03-18 Cadila Healthcare Limited Compuestos que tienen actividades hipolipidémica e hipocolesterolémica, procedimiento para su preparación y composiciones farmacéuticas que los contienen
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
EP2096170B1 (en) * 2005-09-19 2011-08-10 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
WO2008036638A2 (en) * 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. Rnai modulation of scap and therapeutic uses thereof
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
ES2441665T3 (es) 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
MX2013004123A (es) 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
EP3009136A1 (en) * 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (cg-RX-API-DMAC10.html) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (cg-RX-API-DMAC10.html) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009841A1 (en) 2001-07-26 2003-02-06 Cadila Healthcare Limited Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jani, Rajendrakumar H., et al. DIABETES. Vol. 58. 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA: AMER DIABETES ASSOC, 2009
Seo, Yeon Seok, et al. Journal of gastroenterology and hepatology 23.1 (2008): 102-109.

Also Published As

Publication number Publication date
JP2016515608A (ja) 2016-05-30
IL247231A (en) 2017-03-30
MX346943B (es) 2017-04-06
JP6246895B2 (ja) 2017-12-13
EA201592020A1 (ru) 2016-05-31
WO2014174524A1 (en) 2014-10-30
AU2013387996B2 (en) 2015-12-10
US20160166539A1 (en) 2016-06-16
UA114360C2 (uk) 2017-05-25
IL240183A (en) 2016-08-31
BR112015020600A2 (pt) 2017-07-18
IL240183A0 (en) 2015-09-24
AU2013387996A1 (en) 2015-09-24
PH12015501795A1 (en) 2015-11-09
GEP201706663B (en) 2017-05-10
US20180185330A1 (en) 2018-07-05
US20170087127A1 (en) 2017-03-30
CN105377246A (zh) 2016-03-02
CA2900435C (en) 2017-02-14
US9814697B2 (en) 2017-11-14
MA38385A1 (fr) 2017-09-29
HK1214968A1 (zh) 2016-08-12
AP2015008674A0 (en) 2015-08-31
EP2988736A1 (en) 2016-03-02
WO2014174524A8 (en) 2015-10-01
CA2900435A1 (en) 2014-10-30
MX2015010769A (es) 2015-11-26
SG11201506218UA (en) 2015-09-29
KR20150118990A (ko) 2015-10-23
CN105377246B (zh) 2018-03-20
IN2013MU01468A (cg-RX-API-DMAC10.html) 2015-04-17
MY180160A (en) 2020-11-23

Similar Documents

Publication Publication Date Title
KR20150118990A (ko) 비알콜성 지방간 질환을 위한 신규 조성물
US12178799B2 (en) Treatment for primary biliary cholangitis
EP2218712B1 (en) Combination of anti-angiogenic substance and anti-tumor platinum complex
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
CN112755031A (zh) 用于治疗或预防心血管疾病的胆固醇酯转移蛋白抑制剂和含所述抑制剂的药物组合物
ES2973104T3 (es) Combinación de fármacos para su uso en un método de tratamiento de cáncer de hígado
US20220304982A1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
US12201609B2 (en) Saroglitazar for the treatment of hepatocellular carcinoma
EP3923932A1 (en) Treatment for polycystic ovarian syndrome (pcos)
OA17459A (en) A novel composition for nonalcoholic fatty liver disease (NAFLD).
JP7830433B2 (ja) ２型真性糖尿病の制御及び管理のための配合薬剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150907

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150911

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20150911

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151014

Patent event code: PE09021S01D

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160205

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160427

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160428

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190418

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190418

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200416

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210415

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230413

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240418

Start annual number: 9

End annual number: 9